Nearly all SCLC cases show genomic inactivation of TP53 and RB1 (George et al., 2015); thus, phenotypic heterogeneity observed in SCLC cannot be explained based on the mutational status (Rudin et al., 2019). This evidence concerns the gene TP53 and small cell lung carcinoma.